ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA.

about

ECRG2 enhances the anti-cancer effects of cisplatin in cisplatin-resistant esophageal cancer cells via upregulation of p53 and downregulation of PCNA.

Item

http://www.wikidata.org/entity/Q38710182

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

ECRG2 enhances the anti-cancer ...... 53 and downregulation of PCNA.

@en

type

Item

label

ECRG2 enhances the anti-cancer ...... 53 and downregulation of PCNA.

@en

prefLabel

ECRG2 enhances the anti-cancer ...... 53 and downregulation of PCNA.

@en

P1476

ECRG2 enhances the anti-cancer ...... 53 and downregulation of PCNA.

@en

P2093

Chen Wu

http://www.w3.org/2001/XMLSchema#string

Hai-Yan Song

http://www.w3.org/2001/XMLSchema#string

Ju-Feng Wang

http://www.w3.org/2001/XMLSchema#string

Lin-Ping Xu

http://www.w3.org/2001/XMLSchema#string

Shuai Li

http://www.w3.org/2001/XMLSchema#string

Xin-Fang Hou

http://www.w3.org/2001/XMLSchema#string

P2860

ECRG2, a novel candidate of tumor suppressor gene in the esophageal carcinoma, interacts directly with metallothionein 2A and links to apoptosis

Using yeast two-hybrid system to identify ECRG2 associated proteins and their possible interactions with ECRG2 gene

Global cancer statistics, 2012

PCNA: a silent housekeeper or a potential therapeutic target?

Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides

Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation

[Cloning and identification of cDNA fragments related to human esophageal cancer]

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer

Concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil (5-FU) and cisplatin for locally advanced resectable esophageal cancer.

14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules.

P304

1796-1803

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V23.I10.1796

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28348485

http://www.w3.org/2001/XMLSchema#string

P932

5352920

http://www.w3.org/2001/XMLSchema#string